Drug Profile
Research programme: cancer therapeutics - Array BioPharma/Genentech
Latest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma
- Class Methylurea compounds; Pyridines; Small molecules; Urea compounds
- Mechanism of Action Mitogen-activated protein kinase modulators; Proto-oncogene protein c-met inhibitors; Raf kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Jul 2019 Array Biopharma has been acquired by Pfizer
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 01 Sep 2011 Preclinical development is ongoing in USA